Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The Graph price prediction anticipates a high of $0.419 by the end of 2025. In 2028, it will range between $0.978 and $1.12, with an average price of $1.05. In 2031, it will range between $1.68 and $1 ...

Get prepared with the key expectations. Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

Carle Heath is stepping up its specialty care options this month for foot and ankle health at its Eureka hospital.

By The Learning Network A new collection of graphs, maps and charts organized by topic and type from our “What’s Going On in This Graph?” feature. By The Learning Network Want to learn ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

The tech world is buzzing with exciting developments and innovations every day, let's find out what's new has been introduced ...